Crown J, Raptis G, Hamilton N, Hudis C, Vahclat L, Fennelly D, Norton L
St. Vincent's Hospital, Dublin, Ireland.
Can J Oncol. 1995 Dec;5 Suppl 1:80-2.
High-dose chemotherapy (HDC) with stem cell autografting produces complete remission (CR) rates far in excess of those reported for lower-dose chemotherapy, or for any form of endocrine manipulation in patients with metastatic breast cancer. In early studies involving patients with resistant disease, HDC produced CR rates of as high as 25%. Most contemporary HDC trials accrue patients who are responding to "conventional" chemotherapy, and hence, few untreated patients have been studied in phase II evaluations. In one case, a CR rate of 54% (25% of which remained durable) was reported. In a randomized trial of high-dose versus conventionally dosed therapy, investigators in South Africa reported complete response rates of 50% and 6% respectively. In trials in which HDC is applied as a form of consolidation therapy following "conventional" chemotherapy, complete remission rates as high as 70% are reported.
大剂量化疗（HDC）联合自体干细胞移植所产生的完全缓解（CR）率远远超过低剂量化疗或转移性乳腺癌患者任何形式内分泌治疗所报告的缓解率。在早期针对耐药疾病患者的研究中，大剂量化疗产生的CR率高达25%。大多数当代大剂量化疗试验纳入的是对“传统”化疗有反应的患者，因此，在II期评估中很少有未接受治疗的患者被研究。在一个案例中，报告的CR率为54%（其中25%为持久缓解）。在一项高剂量与常规剂量治疗的随机试验中，南非的研究人员分别报告了50%和6%的完全缓解率。在将大剂量化疗作为“传统”化疗后巩固治疗形式的试验中，报告的完全缓解率高达70%。
